(Q39333338)

English

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

Parkinson Study Group

1

object named as

Parkinson Study Group

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

30 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Movement Disorders

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1823-1831

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

'Rejuvenation' protects neurons in mouse models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Stages in the development of Parkinson's disease-related pathology

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Neuronal vulnerability, pathogenesis, and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Use of antihypertensives and the risk of Parkinson disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Use of calcium channel blockers and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Teaching tape for the motor section of the unified Parkinson's disease rating scale

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists

1 reference

https://api.crossref.org/works/10.1002%2FMDS.25639

21 January 2018

Identifiers

10.1002/MDS.25639

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39333338&oldid=1454883252"